Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)

Ahmed A Daak; Carlton D Dampier; Beng Fuh; Julie Kanter; Ofelia A Alvarez; L. Vandy Black; Melissa A McNaull; Michael U Callaghan; Alex George; Lynne Neumayr; Lee M Hilliard; Fredrick Sancilio; Adrian L Rabinowicz; Matthew M Heeney

doi:10.1182/bloodadvances.2018021444

Back

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)

Journal article

Open access

Peer reviewed

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)

Ahmed A Daak, Carlton D Dampier, Beng Fuh, Julie Kanter, Ofelia A Alvarez, L. Vandy Black, Melissa A McNaull, Michael U Callaghan, Alex George, Lynne Neumayr, …

Blood advances, Vol.2(15), pp.1969-1979

2018-08-14

DOI: https://doi.org/10.1182/bloodadvances.2018021444

PMCID: PMC6093734

PMID: 30097463

Abstract

Key Points SC411 increases DHA in blood cell membranes and reduces home-managed SCD pain crisis and analgesic and opioid use at home to treat SCD pain. The rate of sickle cell crisis was 53% lower for the pooled active groups vs placebo.

Files and links (1)

url

https://doi.org/10.1182/bloodadvances.2018021444View

Published (Version of record) Open

Metrics

18 Record Views

25 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.225 Hematologic Diseases; 1.225.626 Sickle Cell Disease
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)
Creators: Ahmed A Daak - Sancilio Pharmaceuticals Company, Inc., Riviera Beach, FL
Carlton D Dampier - Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
Beng Fuh - Department of Pediatrics, East Carolina University, Greenville, NC
Julie Kanter - Division Hematology-Oncology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC
Ofelia A Alvarez - Division of Hematology/Oncology, Department of Pediatrics, University of Miami, Miami, FL
L. Vandy Black - Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL
Melissa A McNaull - Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS
Michael U Callaghan - Children’s Hospital of Michigan, Detroit, MI
Alex George - Texas Children’s Hospital, Houston, TX
Lynne Neumayr - Benioff Children’s Hospital, University of California, San Francisco, Oakland, CA
Lee M Hilliard - Division of Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL; and
Fredrick Sancilio - Sancilio Pharmaceuticals Company, Inc., Riviera Beach, FL
Adrian L Rabinowicz - Sancilio Pharmaceuticals Company, Inc., Riviera Beach, FL
Matthew M Heeney - Division of Hematology/Oncology, Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, MA
Publication Details: Blood advances, Vol.2(15), pp.1969-1979
Academic Unit: Miller School of Medicine; UMMG Department of Pediatrics; UMMG Dept of Pediatrics - Hematology/Oncology/Stem Cell Transp
Language: English
Resource Type: Journal article
PMID: 30097463
PMCID: PMC6093734
Record Identifier: 991031559757402976